1-(4-(3-amino-6-phenylisoxazolo[3,4-b]pyridin-4-yl)phenyl)-3-p-tolylurea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(4-(3-amino-6-phenylisoxazolo[3,4-b]pyridin-4-yl)phenyl)-3-p-tolylurea
• 英文别名: 1-[4-(3-Amino-6-phenyl-[1,2]oxazolo[3,4-b]pyridin-4-yl)phenyl]-3-(4-methylphenyl)urea；1-[4-(3-amino-6-phenyl-[1,2]oxazolo[3,4-b]pyridin-4-yl)phenyl]-3-(4-methylphenyl)urea
• 化学式: C₂₆H₂₁N₅O₂
• 分子量: 435.485
• InChiKey: SOICIUYXTURPCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one 在 tin(II) chloride dihdyrate 、 三丁基膦 、 盐酸羟胺 、 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 1-(4-(3-amino-6-phenylisoxazolo[3,4-b]pyridin-4-yl)phenyl)-3-p-tolylurea
  参考文献：
  名称：

  Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase

  摘要：

  Inspired by that the multi-target inhibitors against receptor tyrosine kinases (RTKs) have significantly improved the effect of clinical treatment for cancer, and based on the chemical structure of Linifanib (ABT-869, Abbott), two series of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure were designed and synthesized as multi-target inhibitors against RTKs. The preliminary biological evaluation showed that several compounds exhibited comparable potency with Linifanib. Compound S21 was identified as the most potent inhibitor against Fms-like tyrosine kinase 3 (FLT-3), kinase insert domain containing receptor (KDR) and platelet-derived growth factor receptor beta (PDGFR-beta) with its IC50 values were 4 nM, 3 nM and 8 nM respectively, it also showed potent inhibitory activities against several cancer cells.

  DOI：

  10.1016/j.bmc.2018.08.013

文献信息

• Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase
  作者：Zhi-Hao Shi、Feng-Tao Liu、Hao-Zhong Tian、Yan-Min Zhang、Nian-Guang Li、Tao Lu

  DOI：10.1016/j.bmc.2018.08.013

  日期：2018.9

  Inspired by that the multi-target inhibitors against receptor tyrosine kinases (RTKs) have significantly improved the effect of clinical treatment for cancer, and based on the chemical structure of Linifanib (ABT-869, Abbott), two series of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure were designed and synthesized as multi-target inhibitors against RTKs. The preliminary biological evaluation showed that several compounds exhibited comparable potency with Linifanib. Compound S21 was identified as the most potent inhibitor against Fms-like tyrosine kinase 3 (FLT-3), kinase insert domain containing receptor (KDR) and platelet-derived growth factor receptor beta (PDGFR-beta) with its IC50 values were 4 nM, 3 nM and 8 nM respectively, it also showed potent inhibitory activities against several cancer cells.